Cardialen: Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy Designed to Treat Dangerous Heart Rhythms
National Institutes of Health grant will support Cardialen's development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke.
Read full article »
Cardialen is a Minnesota-based medical device company that develops implantable cardioversion and defibrillation products for the treatment of atrial fibrillation.
Read more